Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [41] Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
    Oiwa, Ako
    Hiwatashi, Dai
    Takeda, Teiji
    Miyamoto, Takahide
    Kawata, Iori
    Koinuma, Masayoshi
    Yamazaki, Masanori
    Komatsu, Mitsuhisa
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (09) : 2203 - 2210
  • [42] Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes
    Rigalleau, V.
    Cougnard-Gregoire, A.
    Nov, S.
    Gonzalez, C.
    Maury, E.
    Lorrain, S.
    Gin, H.
    Barberger-Gateau, P.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (02) : 270 - 274
  • [43] Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
    Ceriello, Antonio
    Catrinoiu, Doina
    Chandramouli, Chanchal
    Cosentino, Francesco
    Dombrowsky, Annique Cornelia
    Itzhak, Baruch
    Lalic, Nebojsa Malic
    Prattichizzo, Francesco
    Schnell, Oliver
    Seferovic, Petar M.
    Valensi, Paul
    Standl, Eberhard
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [44] Diagnosis and Management of Type 2 Diabetic Kidney Disease
    Doshi, Simit M.
    Friedman, Allon N.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (08): : 1366 - 1373
  • [45] Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future
    Mallik, Ritwika
    Chowdhury, Tahseen A.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [46] Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
    Ashjian, Emily
    Clarke, Megan
    Pogue, Kristen
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (23) : 1708 - 1721
  • [47] Chronic Kidney Disease in the Older Adult Patient with Diabetes
    Ravender, Raja
    Roumelioti, Maria-Eleni
    Schmidt, Darren W.
    Unruh, Mark L.
    Argyropoulos, Christos
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [48] Diabetes Management in Older Adults With Chronic Kidney Disease
    Clemens, Kristin K.
    O'Regan, Niamh
    Rhee, Jinnie J.
    CURRENT DIABETES REPORTS, 2019, 19 (03)
  • [49] Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease
    Wang, Xiangyu
    Zhang, Huijie
    Zhang, Qian
    Guan, Meiping
    Sheng, Shuyue
    Mo, Wei
    Zou, Mengchen
    Li, Jimin
    Bi, Jianlu
    Tang, Xianyu
    Zeng, Huiyan
    He, Jiali
    Xu, Gugen
    Li, Ping
    Xue, Yaoming
    AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (10) : 806 - 814
  • [50] Antihyperglycemic Treatment Patterns for Chronic Kidney Disease and Type 2 Diabetes
    Betts, Keith A.
    Oberprieler, Nikolaus G.
    Wu, Aozhou
    James, Glen
    Beeman, Scott
    Gay, Alain
    He, Xuanhao
    Chen, Jingyi
    Vizcaya, David
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (09) : 405 - 412